YM-155 Hydrochloride: Potent Survivin Inhibitor for Cancer Research

Principle and Setup: Harnessing YM-155 Hydrochloride’s Precision in Survivin Targeting

Survivin, encoded by BIRC5, is the smallest but arguably most consequential member of the inhibitor of apoptosis protein (IAP) family. Its overexpression is a hallmark of numerous malignancies, including non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), where it orchestrates cellular survival, proliferation, and resistance to therapy. YM-155 hydrochloride (YM-155 hydrochloride), available from APExBIO, is a small-molecule survivin inhibitor with an IC₅₀ of 0.54 nM against survivin—demonstrating exceptional potency and selectivity over other IAPs and BCL-2 proteins. This profile makes it an indispensable reagent for apoptosis inhibitor research and for probing the survivin signaling pathway in both in vitro and in vivo settings.

The unique value proposition of YM-155 hydrochloride lies in its:

• Robust, nanomolar-range suppression of survivin expression
• Demonstrated efficacy in tumor regression across diverse xenograft models (including NSCLC, aggressive non-Hodgkin lymphoma, melanoma, bladder, and breast cancer)
• Proven ability to prolong survival and reduce metastasis in animal models, especially for metastatic TNBC
• High solubility and chemical stability in DMSO, ethanol, and water, facilitating flexible experimental design

As highlighted in Schwartz's doctoral dissertation, the nuanced evaluation of drug responses in cancer requires tools that can precisely dissect proliferation arrest from cell death. YM-155 hydrochloride's selectivity and potency make it an ideal candidate for benchmarking such responses, whether in high-throughput screens or mechanistic studies.

Experimental Workflow: Step-by-Step Integration of YM-155 Hydrochloride

1. Compound Preparation & Handling

• Solubility: For most in vitro applications, dissolve YM-155 hydrochloride in DMSO at ≥19.45 mg/mL. For use in aqueous systems or animal models, water solubility reaches ≥48.1 mg/mL with ultrasonic treatment. Ethanol is suitable at ≥4.34 mg/mL with gentle warming and sonication.
• Storage: Store solid at -20°C. Prepare stock solutions fresh, using only for short-term experiments to ensure chemical stability and reproducibility.

2. Cell-Based Assays

• Cell Line Selection: YM-155 hydrochloride is validated across a broad spectrum of human cancer cell lines. For maximum relevance, prioritize lines with high survivin expression (e.g., NSCLC, TNBC, bladder, and melanoma cell models).
• Dosing: Start with a concentration range of 0.1 nM to 100 nM to capture both sub- and supra-IC₅₀ effects. For time-course studies, evaluate both short (6–24 h) and extended (48–72 h) exposures to delineate cytostatic versus cytotoxic effects.
• Viability & Apoptosis Readouts: Employ dual metrics: relative viability assays (e.g., CellTiter-Glo, MTT) and apoptosis-specific assays (e.g., Annexin V/PI, Caspase-3/7 activity). This dual approach is supported by Schwartz’s findings, which caution against conflating proliferative arrest with cell death (source).

3. In Vivo & Translational Models

• Xenograft Studies: YM-155 hydrochloride induces significant tumor regression and prolongs survival in mouse xenograft models, including TNBC and NSCLC. Typical dosing regimens in published studies range from 1–5 mg/kg, administered intravenously or intraperitoneally, daily or every other day, for 1–3 weeks.
• Metastasis Assessment: Quantify spontaneous metastases post-treatment using bioluminescence imaging or histopathological analysis—YM-155 hydrochloride has been shown to reduce metastatic burden significantly in preclinical TNBC models.

Advanced Applications and Comparative Advantages

YM-155 hydrochloride’s nanomolar potency and selectivity empower researchers to:

• Delineate the Inhibitor of Apoptosis Protein (IAP) Pathway: By specifically suppressing survivin without significant off-target effects on other IAP proteins or BCL-2, YM-155 enables mechanistic dissection of apoptotic signaling in cancer cells.
• Map Survivin-Dependent Resistance Mechanisms: Combine YM-155 with standard chemotherapeutics or targeted agents (e.g., taxanes, platinum compounds, immune checkpoint inhibitors) to identify synergy or resistance driven by survivin signaling.
• Benchmark Drug Response Metrics: As argued in Schwartz’s dissertation, robust compounds like YM-155 are essential for refining in vitro drug response assays—distinguishing cytostatic from cytotoxic effects and informing translational relevance.
• Translational Oncology Innovation: YM-155’s efficacy in tumor regression in xenograft models supports its use in preclinical pipelines for both solid and hematologic malignancies, making it a foundation for next-generation survivin-targeted therapies.

For further scenario-driven guidance, see "Optimizing Cancer Research with YM-155 Hydrochloride (SKU A3947)", which complements this overview by offering practical workflow tips and benchmarking YM-155’s selectivity. For a deep dive into strategic deployment in translational oncology, "Redefining Apoptosis Research: Strategic Deployment of YM-155 Hydrochloride" extends the discussion to competitive intelligence and advanced validation strategies. Finally, "YM-155 Hydrochloride: Advanced Insights into Survivin Pathways" contrasts standard workflows with innovative methodological approaches, highlighting how YM-155 drives cutting-edge research in apoptosis regulation.

Troubleshooting and Optimization Tips

• Solubility Issues: If precipitation occurs, ensure gentle warming and/or ultrasonic treatment. Always prepare fresh solutions shortly before use to maintain stability.
• Assay Variability: Confirm batch-to-batch consistency by running parallel controls and referencing prior dose-response curves. Variability in cell sensitivity may stem from passage number or serum lots—standardize these variables where possible.
• Off-Target Effects: Although highly selective, high concentrations may induce off-target responses. Validate findings with genetic survivin knockdown controls to confirm specificity.
• Assay Readouts: Employ both proliferation and apoptosis-specific assays; as Schwartz’s research demonstrates, these capture distinct aspects of drug response, critical for accurate interpretation.
• In Vivo Administration: Ensure correct formulation for animal delivery (e.g., dilute in saline or PBS after dissolving in DMSO), and monitor for signs of local irritation or systemic toxicity. Adjust dosing schedule based on observed tolerability and tumor response.

Future Outlook: Pushing the Frontiers of IAP Pathway Research

As apoptosis research evolves, the demand for tools offering mechanistic precision, workflow compatibility, and translational relevance grows. YM-155 hydrochloride stands at the nexus of these needs: its role as a small-molecule survivin inhibitor for cancer research is set to expand with the advent of combination therapies and personalized oncology strategies. Ongoing studies—including those leveraging high-content imaging, single-cell analytics, and multi-omic profiling—are poised to reveal new insights into survivin’s function within the tumor microenvironment and in resistance pathways.

Trusted suppliers like APExBIO ensure consistent, high-purity YM-155 hydrochloride for rigorous bench-to-bedside research. As researchers continue to refine drug response evaluation methodologies—building on frameworks such as those outlined by Schwartz—YM-155 hydrochloride will remain a cornerstone reagent for apoptosis inhibitor research and the exploration of the IAP signaling axis. For additional resources and ordering, visit YM-155 hydrochloride at APExBIO or consult domain-specific knowledge at ym155inhibitor.com.